• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 av

tetano

Editor, Senior Moderator
Biotechnol J. 2013 Jul 1. doi: 10.1002/biot.201300116. [Epub ahead of print]
Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses.
Lin SC, Liu WC, Lin YF, Huang YH, Liu JH, Wu SC.
Source

Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan.
Abstract

Highly pathogenic avian influenza (HPAI) H5N1 viruses continue to trigger severe diseases in poultry and humans, prompting many efforts to develop an effective vaccine. Toward that goal, we employed two modern sophisticated techniques namely construction of recombinant adenovirus vector encoding HA (rAd-HA) and flagellin-containing virus-like particle (FliC-VLP). Using a murine model, we investigated a heterologous prime-boost regimen of rAd-HA vector and FliC-VLP in contrast to two-dose immunizations using rAd-HA or FliC-VLP alone. Our results indicate that priming with rAd-HA vector followed by a FliC-VLP booster induced the highest levels of HA-specific total IgG, IgG1, IgG2a, hemagglutination inhibition and neutralizing antibody titers against homologous and heterologous clades of H5N1 virus strains. These results provide useful information to support the development of more effective H5N1 vaccines.

Copyright ? 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
KEYWORDS:

H5N1 vaccine, VLP, adenovirus, prime-boost immunization

PMID:
23813782
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23813782
 
Back
Top Bottom